Now Approved: U.S. FDA approves product to reduce the incidence of catheter-related bloodstream infections (CRBSIs) under special pathway for patients receiving hemodialysis.

Phoebe Mounts, Esq.

September 1, 2022

Phoebe Mounts was appointed Executive Vice President and General Counsel in May 2019. She leads the company’s legal, compliance and regulatory affairs activities. Prior to joining CorMedix, Dr. Mounts was a partner at the law firm Morgan Lewis and Bockius LLP where since 2013 she advised the company with respect to its U.S. Food and Drug Administration (FDA) regulatory strategies for DefenCath™ and taurolidine. Dr. Mounts is a graduate of Georgetown University Law Center, prior to which she was on the faculty of the Johns Hopkins University School of Public Health for 16 years, specializing in molecular biology and infectious disease. She received her Ph.D. in molecular biology from the University of Edinburgh in Scotland.